P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS

• Prithviraj Bose,
• Sanjay Mohan,
• Stephen Oh,
• Jason Gotlib,
• Ellen Ritchie,
• Taizo Shimomura,
• Haris Ali,
• Francoise Boyer,
• Paola Guglielmelli,
• Anthony M. Hunter,
• Betty Lamothe,
• Yi Cui,
• Francis Seguy,
• Amanda Mcbride,
• Francesca Palandri,
• Masahiro Takeuchi,
• Jean-Jacques Kiladjian

Affiliations

Prithviraj Bose

1 The University of Texas MD Anderson Cancer Center, Houston, United States

Sanjay Mohan

2 Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville

Stephen Oh

3 Siteman Cancer Center, Washington University School of Medicine, St. Louis, United States

Jason Gotlib

4 Stanford Cancer Institute, Stanford, United States

Ellen Ritchie

5 Weill Cornell Medical College, Cornell University, New York, United States

Taizo Shimomura

6 Kumamoto Shinto General Hospital, Kumamoto, Japan

Haris Ali

7 City of Hope, Duarte, United States

Francoise Boyer

8 Centre Hospitalier Universitaire Angers, Angers, France

Paola Guglielmelli

9 CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy

Anthony M. Hunter

10 Winship Cancer Institute, Emory University School of Medicine, Atlanta, United States

Betty Lamothe

11 Incyte Corporation, Wilmington, United States

Yi Cui

11 Incyte Corporation, Wilmington, United States

Francis Seguy

12 Incyte Biosciences International Sàrl, Morges, Switzerland

Amanda Mcbride

11 Incyte Corporation, Wilmington, United States

Francesca Palandri

13 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

Masahiro Takeuchi

14 Chiba Cancer Center, Chiba, Japan

Jean-Jacques Kiladjian

15 Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Université Paris Cité, Inserm, Paris, France